INTRODUCTION
More than 600 million people worldwide are infected with malaria (WHO, 2003) and an average of 1 to 2 million die every year, most of them are below the age of five. Several non-ACTs (artemisinin-based combination therapies) have been used to fight this infectious disease, but only ACTs have continued to show efficacy with no or minimal reported cases of resistance (Bonifacio, 2004.) .
Malaria is one of the leading causes of morbidity and mortality worldwide (Snow et al., 2005) . The spread of parasite resistance to first-line drugs adds to the burden of the disease (Greenwood et al., 2005) . A contributing factor has been the continued use of failing drugs, partly *Corresponding author. E-mail: adewuyio@yahoo.co.uk.
because of the difficulty to assess their efficacy in vivo. Methodological issues still being debated include how long patients should be monitored after treatment and whether clinical or parasitological outcomes should be given greater weight. Methods used so far differ greatly, making comparison and synthesis of data very difficult (Talisuma et al., 2004) . The WHO has issued different sets of guidelines, shifting emphasis with time from parasitological to clinical assessment and more recently recommending that patients be assessed both parasitologically (WHO, 1973) and clinically (WHO, 1996) and monitored for 28 days if true failures are to be distinguished from new infections; it also makes provision for the use of life table analysis of results (WHO, 2003) .
Malaria is one of the three major infectious diseases along with tuberculosis and AIDS (Greenwood et al., 2005) . After World War II, the successful use of chloroquine as an efficient antimalaria drug against the 4 strains of human Plasmodia (vivax, malariae, ovale and falciparum) and the cheap DDT insecticide significantly reduced the importance of this tropical disease up to 1960. Unfortunately, the emergence of parasite strains resistant to chloroquine and other classical drugs was at the origin of the comeback of malaria (>200 million people are infected each year and there are >1 million deaths) (White et al., 1999) . Resistance of mosquitoes to some insecticides has been documented just within a few years after the insecticides were introduced. There are over 125 mosquito species with documented resistance to one or more insecticides. The development of resistance to insecticides used for indoor residual spraying was a major impediment during the Global Malaria Eradication Campaign. Judicious use of insecticides for mosquito control can limit the development and spread of resistance. However, use of insecticides in agriculture has often been implicated as contributing to resistance in mosquito populations (CDC, 2004) .
Fortunately, antimalarial drug research is active again after a decline period of several decades (Nwaka and Ridley, 2003) . The renewal of activity in this field is caused mainly by the design of new small molecules active against chloroquine-resistant (CQR) strains of Plasmodium falciparum. With a chemical structure significantly different from that of quinoline-based drugs, the natural product artemisinin and its derivatives have attracted the attention of many different groups regarding the mechanism of action of these potent antimalarias devoid of significant clinical resistance up to now in Africa (Meshnick et al., 1996; Robert et al., 2005; Olliaro et al., 2001; Wu, 2002; Eckstein-Ludwig et al., 2003) . Artemisinin, with its 1,2,4-trioxane as active motif, has served as a source of motivation for the design of synthetic peroxide-containing drugs (Jefford, 2007; Posner et al., 2008; O'Neill and Posner, 2004; Vennerstrom et al., 2004; Singh et al., 2006) . Artemisinin (qinghaosu) has been used for centuries in traditional Chinese medicine for the treatment of fever. In 1972, Chinese scientists isolated the active principle from the plant Artemisia annua. Artemisinin is a sesquiterpene lactone charac-terized by the presence of an endoperoxide that is associated with its potent antimalarial activity. Because artemisinin is chemically unstable and poorly soluble in water or oil, the carbonyl group at C-10 of the parent compound is often reduced to obtain dihydroartemisinin. Several derivatives have been developed by adding ether, ester or other substituents to the hydroxyl group of dihydroartemisinin. These semisynthetic derivatives include water soluble derivatives, sodium artesunate and artelinic acid and the oil-soluble derivatives, artemether and arteether. With the exception of arteether and artelinic acid, these compounds are used to treat malarial infections in endemic countries (Ringwald et al., 1999) . Artemisinin derivatives are available Adewuyi et al. 13029 in different formulations for oral, parenteral and rectal administration. Clinical studies have shown that artemisinin derivatives are highly potent, rapidly acting and well-tolerated blood schizontocides, resulting in short parasite clearance times as compared to other antimalarial drugs. Artemisinin derivatives are highly effective against P. falciparum isolates that are resistant to other drugs. These derivatives are indicated for the emergency treatment of severe and complicated falciparum malarial by parenteral administration and for the oral treatment of uncomplicated multidrug-resistant malaria. All the artemisinin derivatives are metabolized rapidly to the active metabolite dihydroartemisinin, which is more active than the other artemisinin derivatives. The use of dihydroartemisinin instead of the substitute compounds (example, artesunate or artemether) has advantages. The drug is easy to produce with less synthetic steps, and thus a lower cost (http:/www.Rdi. gpo.or.th/htmls/dihyro.html). Dihydroartemisinin is thermally labile, lacks ultraviolet absorbence or fluorescent chromophore and does not possess functional groups for derivatization. Therefore, the development of sensitive and specific analytical methods for determination of dihydroar-temisinin is a challenging problem. Several techniques have been used to address this problem, such as gas chromatography (GC), and gas chromatography combined with mass spectrophotometry, e.t.c. However, presently, there is no cheap, simple and reliable analytical method available, which can be used to follow up the history of people undergoing a treatment as well as to identify counterfeit and substandard antimalarial drugs in circulation. Furthermore, there is no single simple semi-quantitative method, which can be used to detect more than one anti-malarial drug using the same test system and conditions. This means that there is a shortage of simple and convenient analytical methods for monitoring antimalarial drug quality, usage, adequate absorption and excretion (Bojang et al., 2005) . The purpose of this research was to establish and validate, in accordance with International Conference on Harmoni-zation (ICH) guidelines, a routine, simple, precise, economical and reproducible thin layer chromatographic technique for the detection of artesunate and amodiaquine in commercial antimalarial drugs.
MATERIALS AND METHODS

Sample collection
The antimalarial drugs-artesunate and amodiaquine, were generous gift from the Department of Paediatrics, University College Hospital, Ibadan.
Preparation of stock solution of artesunate and amodiaquine
One tablet of commercial artesunate tablet containing 5 mg of artesunate was dissolved in 50 ml of dimethyl sulfoxide (DMSO), to obtain a stock containing 50 mg/50 ml of artesunate in DMSO. One tablet of commercial base amodiaquine tablet containing 200 mg of amodiaquine in the form of a base was dissolved in 50 ml of dimethylsulfoxide (DMSO), to give a stock containing 200 mg/50 ml of amodiaquine in DMSO.
Preparation of calibration curves
To prepare the calibration curve for the artesunate, accurately measured aliquots were taken from the stock solution, each aliquot corresponding to 0. 001, 0.00125, 0.0025, 0.005, 0.01, 0.0125, 0.025, 0.05, 0.1, 0.125, 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6 .0 mg/ml, respectively. Different solvents and solvent combinations were tested for their abilities to separate the drugs from excipients in their formulations. Some of the tested solvent combinations include, ethyl acetate: toluene, ethyl acetate: toluene: isopropanol, hexane: toluene: paraffin mixtures. However, the plates were developed with 50 ml of paraffin-n hexane mixture 2:3 (v/v). To prepare the calibration curve for amodiaquine, accurately measured aliquots was taken from the stock solution, each aliquot corresponding to 0.05, 0.1, 0.125, 0.25, 0.5, 1.0, 2.0, 3.0, 4.0 and 5.0 mg/ml, respectively. Different solvents and solvent combinations were tested. Some of the tested solvent combinations include: isopropanol-n hexane, cyclohexanol-toluene, methylamine-n hexane, ethyacetate-toluene-isopropanol, hexane-toluene-paraffin mixtures, tetrahydrofuran-paraffin-cyclohexanol-water and tetrahydrofuran-paraffin-isopropanol-cyclohexanol. However, the plates were developed with 50 ml of ethyacetate-toluene mixture (2.5: 47.5) (v/v).
Spotting of the TLC plates
A 20 × 20 cm prepared glass TLC plates were used for the separations. Samples were spotted on the TLC plates at a distance of 1 cm apart and a distance of 1 cm from the edge and bottom of the plate.
Development of the spotted TLC plates
The spotted plate was developed in a chromatographic tank with paraffin-n hexane mixture, 2:3 (v/v) as mobile phase for artesunate and ethyacetate-toluene mixture, 2.5: 47.5 (v/v) as mobile phase for amodiaquine. The plate was allowed to develop for 20, 22 and 25 min at a development distance of 10.0, 10.4 and 10.8 cm, respectively, for artesunate and 9.4, 12.5 and 12.8 cm, respectively, for amodiaquine, for both intraday and interday determinations. After separations, the plates were allowed to dry at ambient temperature for 5 min and then transferred to the iodine tank for colour development. The development time was 25 min. The retention factor (Rf) values were determined for each concentration of the sample solution as presented in Table 1 .
The procedure was repeated twice on the same day and repeated also on three different days in a space of two weeks.
Method validation
The method was validated for linearity, specificity, intra-day and inter-day precision, repeatability of measurement of peak area, and repeatability of sample application, in accordance with International Conference on Harmonisation (ICH) guidelines (ICH, 1994) . The robustness of the method was studied, during method development, by determining the effects of small variations of mobile phase composition (+2%), development chamber saturation period and development distance as shown in Table 3 . Intra-day precision was determined by analysis of solutions of artesunate and amodiaquine in the range of 0.1 to 6.0 mg/ml, three times on the same day (Tables 2a and 4a and b). Inter-day precision was determined by analysis of similar standards on three different days over a period of two weeks. Relative standard deviation (RSD) was calculated for both series of analyses. 
RESULTS AND DISCUSSION
Tablet powder of artesunate and amodiaquine were pulverized and dissolved in dimethylsulfoxide. Several solvents for example, ethyl acetate-toluene, ethyl acetate-toluene-isopropanol, hexane-toluene-paraffin mixtures and Isopropanol-n hexane, cyclohexanoltoluene, methylamine-n hexane, ethyl acetate-tolueneisopropanol, hexane-toluene-paraffin mixtures, tetrahydrofuran-paraffin-cyclohexanol-water, tetrahydrofuranparaffin-isopropanol-cyclohexanol were investigated for the separation of artesunate and amodiaquine, respectively from excipients in their formulation. Paraffinn hexane 2:3 (v/v) and ethyl acetate-toluene 2.5:47.5 Table 2b . Data for amodiaquine retention factor (Rf) values (Day 2). (v/v) were found to result in best peak shapes for artesunate and amodiaquine, respectively. Artesunate and amodiaquine were satisfactorily resolved with retention factor (Rf) values ranging from 0.03-0.06 ± 0.02-0.03 and 0.02-0.1 ± 0.01-0.07, respectively ( Figures  1 and 2 ). Pre-saturation of the TLC chamber and iodine chamber with mobile phase vapour and iodine vapour, respectively for 20 to 30 min ensured more reproducible migration of the drugs and better resolution. As recommended by International Conference on Harmonization (ICH, 1994) , calibration plots were established for artesunate and amodiaquine standards using seventeen concentrations (0.001, 0.00125, 0.0025, 0.005, 0.01, 0.0125, 0.025, 0.05, 0.1, 0.125, 0.25, 0.5, Tables 5a and b . To test the specificity of the method, certain concentrations of artesunate and amodiaquine were spotted on the TLC plates and developed separately; this was repeated thrice for the same concentration. Excipients present in both formulations did not interfere with the peaks of artesunate and amodiaquine. When small changes were made to the method conditions, there were no marked changes in chromatographic behaviour, indicating that the method is robust. Correlations were fairly good. A relatively weak to fairly good linear association (R 2 = 0.36 to 0.80) was observed between artesunate concentrations and their retention factors (Rf) and a fairly good linear association (R 2 = 0.59 -0.89) was observed for amodiaquine concentrations and their retention factors (Rf) values. The intraday and interday relative standard deviations (RSD) were in the ranges of 10.7 to 25.8% and 10.7 to 20.2% for artesunate and 8.2 to 19.74% and 8.2 to 37.3% for amodiaquine. RSD for measurement of peak area was 12.9 and 8.74% for artesunate and amodiaquine, respectively. The detection limit was measured as the lowest concentration resulting to the lowest observable TLC peak height. According to this rule, artesunate and amodiaquine exhibited a detection limit of 0.001 and 0.05 mg/ml, respectively. These results were reproducible and the precisions were negligible.
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Conclusion
It is shown that our new TLC method achieved reproducibility, repeatability, linearity and selectivity that compares favourably with those of GC, GC-MS, HPLC, HPTLC, spectrophotometry and other methods reported regularly in literatures. The results also meet ICH guidelines (ICH, Q2A and ICH, Q2B) for validation of pharmaceutical TLC methods. The proposed TLC method is simpler, less expensive, routine, more rapid, and more flexible than GC-MS and HPLC.
